Author Topic: (Abst.) CCSVI & MS: comprehensive meta-analysis of case-control studies  (Read 126 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Therapeutic Advances in Neurological Disorders, March 2014:

Quote
Chronic cerebrospinal venous insufficiency and multiple sclerosis: a comprehensive meta-analysis of case–control studies

Georgios Tsivgoulis
Second Department of Neurology, ‘Attikon’ Hospital, School of Medicine, University of Athens, Iras 39, Gerakas Attikis, 15344, Athens, Greece and International Clinical Research Center, St Anne’s University Hospital Brno, Brno, Czech Republic

Theodoros N. Sergentanis
Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Athens, Greece

Andrew Chan
Department of Neurology, Ruhr University, St Josef-Hospital, Bochum, Germany

Konstantinos Voumvourakis
Second Department of Neurology, ‘Attikon’ Hospital, School of Medicine, University of Athens, Athens, Greece

Nikos Triantafyllou
First Department of Neurology, ‘Eginition’ Hospital, School of Medicine, University of Athens, Athens, Greece

Theodora Psaltopoulou
Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Athens, Greece

Ralf Gold
Department of Neurology, Ruhr University, St Josef-Hospital, Bochum, Germany

Christos Krogias
Department of Neurology, Ruhr University, St Josef-Hospital, Bochum, Germany

tsivgoulisgiorg@yahoo.gr


Objectives:

Chronic cerebrospinal venous insufficiency (CCSVI) has recently been implicated in the pathogenesis of multiple sclerosis (MS). This comprehensive meta-analysis of case–control studies investigates the association of CCSVI with MS.

Methods:

Through Medline, EMBASE and Cochrane database searches, case–control ultrasound studies comparing CCSVI frequency among patients with MS and healthy controls were identified.

Results:

We identified 19 eligible studies including 1250 patients with MS and 899 healthy controls. The pooled analysis showed that CCSVI was associated with MS [odds ratio (OR) 8.35; 95% confidence interval (CI) 3.44–20.31; p < 0.001) with considerable heterogeneity across studies (I 2 = 80.1%). This association was substantially attenuated in sensitivity analyses excluding studies that were carried out by the group that originally described CCSVI, included investigators who had also been involved in publications advocating endovascular procedures for CCSVI treatment, or were conducted in Italy. Our most conservative sensitivity analysis combining different exclusion criteria yielded no association of CCSVI with MS (OR 1.35; 95% CI 0.62–2.93; p = 0.453) without any heterogeneity (I 2 = 0%).

Conclusion:

There is considerable heterogeneity across different case–control studies evaluating the association of CCSVI and MS. The greatest factor contributing to this heterogeneity appears to be the involvement of investigators in other publications supporting endovascular procedures as a novel MS treatment.

The abstract can probably be seen here.
« Last Edit: March 01, 2014, 09:46:32 am by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.